- Home
- CYCN vs ENSC Comparison
CYCN vs ENSC Comparison
Compare CYCN & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- ENSC
- Stock Information
- Founded
- CYCN 2018
- ENSC 2003
- Country
- CYCN United States
- ENSC United States
- Employees
- CYCN N/A
- ENSC N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- CYCN Health Care
- ENSC Health Care
- Exchange
- CYCN Nasdaq
- ENSC Nasdaq
- Market Cap
- CYCN 7.6M
- ENSC 6.4M
- IPO Year
- CYCN N/A
- ENSC N/A
- Fundamental
- Price
- CYCN $2.53
- ENSC $2.39
- Analyst Decision
- CYCN
- ENSC
- Analyst Count
- CYCN 0
- ENSC 0
- Target Price
- CYCN N/A
- ENSC N/A
- AVG Volume (30 Days)
- CYCN 1.1M
- ENSC 108.5K
- Earning Date
- CYCN 11-13-2025
- ENSC 11-11-2025
- Dividend Yield
- CYCN N/A
- ENSC N/A
- EPS Growth
- CYCN N/A
- ENSC N/A
- EPS
- CYCN N/A
- ENSC N/A
- Revenue
- CYCN $2,174,000.00
- ENSC $7,413,722.00
- Revenue This Year
- CYCN N/A
- ENSC N/A
- Revenue Next Year
- CYCN N/A
- ENSC $1,354.55
- P/E Ratio
- CYCN N/A
- ENSC N/A
- Revenue Growth
- CYCN N/A
- ENSC 415.58
- 52 Week Low
- CYCN $1.27
- ENSC $1.62
- 52 Week High
- CYCN $9.47
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- CYCN 50.11
- ENSC 58.50
- Support Level
- CYCN $2.17
- ENSC $2.35
- Resistance Level
- CYCN $2.59
- ENSC $2.64
- Average True Range (ATR)
- CYCN 0.33
- ENSC 0.16
- MACD
- CYCN -0.01
- ENSC 0.02
- Stochastic Oscillator
- CYCN 23.53
- ENSC 51.79
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.